NASDAQ:KNSA - Kiniksa Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$17.62 -0.05 (-0.28 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$17.62
Today's Range$17.44 - $17.97
52-Week Range$13.04 - $32.88
Volume68,202 shs
Average Volume288,405 shs
Market Capitalization$953.95 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Receive KNSA News and Ratings via Email

Sign-up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KNSA
CUSIPN/A
CIKN/A
Phone781-439-9100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees47
Market Cap$953.95 million
Next Earnings Date2/28/2019 (Estimated)
OptionableNot Optionable

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) announced its earnings results on Thursday, November, 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.03. View Kiniksa Pharmaceuticals' Earnings History.

When is Kiniksa Pharmaceuticals' next earnings date?

Kiniksa Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Kiniksa Pharmaceuticals.

What price target have analysts set for KNSA?

4 equities research analysts have issued twelve-month price targets for Kiniksa Pharmaceuticals' shares. Their forecasts range from $29.00 to $44.00. On average, they expect Kiniksa Pharmaceuticals' share price to reach $35.3333 in the next year. This suggests a possible upside of 100.5% from the stock's current price. View Analyst Price Targets for Kiniksa Pharmaceuticals.

What is the consensus analysts' recommendation for Kiniksa Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kiniksa Pharmaceuticals.

Has Kiniksa Pharmaceuticals been receiving favorable news coverage?

Press coverage about KNSA stock has been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kiniksa Pharmaceuticals earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.

Who are some of Kiniksa Pharmaceuticals' key competitors?

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Myokardia (MYOK), Exelixis (EXEL), Concert Pharmaceuticals (CNCE), Fate Therapeutics (FATE), Miragen Therapeutics (MGEN), TRACON Pharmaceuticals (TCON), Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD), GlycoMimetics (GLYC) and AbbVie (ABBV).

Who are Kiniksa Pharmaceuticals' key executives?

Kiniksa Pharmaceuticals' management team includes the folowing people:
  • Mr. Sanj K. Patel, CEO & Chairman (Age 49)
  • Mr. Stephen Mahoney, Pres & COO (Age 48)
  • Dr. John F. Paolini, Chief Medical Officer (Age 54)
  • Mr. Chris Heberlig, Chief Financial Officer (Age 44)
  • Mark Ragosa, VP of Investor Relations

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Hillhouse Capital Advisors Ltd. (2.57%), BlackRock Inc. (1.30%), Millennium Management LLC (0.20%), Victory Capital Management Inc. (0.17%), Foresite Capital Management IV LLC (0.12%) and Alps Advisors Inc. (0.07%). Company insiders that own Kiniksa Pharmaceuticals stock include Bros Advisors Lp Baker, Cormorant Asset Management, Lp and James E Flynn. View Institutional Ownership Trends for Kiniksa Pharmaceuticals.

Which institutional investors are selling Kiniksa Pharmaceuticals stock?

KNSA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Victory Capital Management Inc. and Foresite Capital Management IV LLC. View Insider Buying and Selling for Kiniksa Pharmaceuticals.

Which institutional investors are buying Kiniksa Pharmaceuticals stock?

KNSA stock was acquired by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors Ltd., BlackRock Inc., Virtus ETF Advisers LLC, Algert Global LLC, Bank of America Corp DE, D. E. Shaw & Co. Inc., Alps Advisors Inc. and Rhumbline Advisers. Company insiders that have bought Kiniksa Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Cormorant Asset Management, Lp and James E Flynn. View Insider Buying and Selling for Kiniksa Pharmaceuticals.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $17.62.

How big of a company is Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals has a market capitalization of $953.95 million. Kiniksa Pharmaceuticals employs 47 workers across the globe.

What is Kiniksa Pharmaceuticals' official website?

The official website for Kiniksa Pharmaceuticals is http://www.kiniksa.com.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 781-439-9100 or via email at [email protected]


MarketBeat Community Rating for Kiniksa Pharmaceuticals (NASDAQ KNSA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Kiniksa Pharmaceuticals and other stocks. Vote "Outperform" if you believe KNSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel